Tenax Therapeutics Secures Levosimendan Supply, Extends Key License Milestone to 2035
TENX has more than doubled off its 52-week low of $5.66.
Summary
Tenax Therapeutics has finalized two critical agreements with Orion for its oral levosimendan program. The company secured a supply agreement for manufacturing and extended the U.S. regulatory approval milestone for its license agreement to December 31, 2035. This news follows an 8-K filed earlier today detailing these developments. The supply pact ensures manufacturing continuity for a key product, while the license extension significantly defers a potential termination right, providing a much longer runway for regulatory success and commercialization. This is a material positive for the company's core pipeline asset.
At the time of this announcement, TENX was trading at $14.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.9M. The 52-week trading range was $5.66 to $18.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.